SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-131357
Filing Date
2022-12-30
Accepted
2022-12-30 16:18:24
Documents
12
Period of Report
2022-12-29
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2233618d1_8k.htm   iXBRL 8-K 29515
  Complete submission text file 0001104659-22-131357.txt   203595

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA srne-20221229.xsd EX-101.SCH 3069
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20221229_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20221229_pre.xml EX-101.PRE 22619
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2233618d1_8k_htm.xml XML 3486
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 221502167
SIC: 2836 Biological Products, (No Diagnostic Substances)